Stock listing

Hanover:26CA ImmunityBio, Inc. Aktie

German listing (Hanover) of ImmunityBio, Inc. · home listing NASDAQ:IBRX

Follow ImmunityBio, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:IBRX

$9.18 USD -0.82 (-8.2%)

Delayed at least 15 minutes · 4:26 PM EDT, Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IBRX

ImmunityBio, Inc. logo
Ticker
Hanover:26CA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Hanover
Currency
EUR

What changed lately

Latest news

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

Oct 16, 2026

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

Oct 14, 2026

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

Oct 8, 2026

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

Aug 10, 2026

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

Aug 4, 2026

ImmunityBio Receives United Arab Emirates Marketing Authorization for ANKTIVA across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

Jul 30, 2026

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Jun 1, 2026

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

May 22, 2026

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation

May 22, 2026

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

May 19, 2026

All ImmunityBio, Inc. news

Decks

ImmunityBio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
48 in the last 12 months · 202 in all · newest Oct 16, 2026 · oldest 2019
Decks
9 decks · latest August 2026

Where ImmunityBio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IBRX · Home listingNASDAQUnited StatesUSD
gettex:26CAgettexGermanyEUR
LS Exchange:A2QQ2ELS ExchangeGermanyEUR
Tradegate:26CATradegateGermanyEUR
BOATS:IBRXBOATSUnited StatesUSD
Frankfurt:26CAFrankfurtGermanyEUR
Lang & Schwarz:A2QQ2ELang & SchwarzGermanyEUR
Dusseldorf:26CADusseldorfGermanyEUR
Stuttgart:26CAStuttgartGermanyEUR
Munich:26CAMunichGermanyEUR
Hamburg:26CAHamburgGermanyEUR
Hanover:26CA · This pageHanoverGermanyEUR
Xetra:26CAXetraGermanyEUR

Log in to ask 6ix AI your own questions about ImmunityBio, Inc.